Author/Creator: Bothner, Ulrich - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Bothner, Ulrich

1. Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists. Issue 8 (13th May 2022)

Authors:: Rebordosa, Cristina; Farkas, Dóra Körmendiné; Montonen, Jukka; Laugesen, Kristina; Voss, Florian; Aguado, Jaume; Bothner, Ulrich; Rothman, Kenneth J.; Zint, Kristina; Mines, Daniel; Ehrenstein, Vera
Journal:: Pharmacoepidemiology and drug safety
Issue:: Volume 31:Issue 8(2022)
Page Start:: 827
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol. (December 2017)

Authors:: Koch, Andrea; Watz, Henrik; Maleki-Yazdi, M.; Bothner, Ulrich; Tetzlaff, Kay; Voß, Florian; McGarvey, Lorcan
Journal:: NPJ primary care respiratory medicine
Issue:: Volume 27(2017)
Page Start:: 1
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. (October 2018)

Authors:: Andreas, Stefan; Bothner, Ulrich; Trampisch, Matthias; Haensel, Michaela; Buhl, Roland; Alter, Peter
Journal:: Pulmonary pharmacology & therapeutics
Issue:: Volume 52(2018)
Page Start:: 1
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. (January 2017)

Authors:: Buhl, Roland; Magder, Sheldon; Bothner, Ulrich; Tetzlaff, Kay; Voß, Florian; Loaiza, Lazaro; Vogelmeier, Claus F.; McGarvey, Lorcan
Journal:: Respiratory medicine
Issue:: Volume 122(2017)
Page Start:: 58
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. (3rd September 2015)

Authors:: McGarvey, Lorcan; Niewoehner, Dennis; Magder, Sheldon; Sachs, Paul; Tetzlaff, Kay; Hamilton, Alan; Korducki, Lawrence; Bothner, Ulrich; Vogelmeier, Claus; Koch, Andrea; Ferguson, Gary T.
Journal:: COPD
Issue:: Volume 12:Number 5(2015:Oct.)
Page Start:: 484
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. (October 2018)

Authors:: Ferguson, Gary T.; Buhl, Roland; Bothner, Ulrich; Hoz, Alberto de la; Voß, Florian; Anzueto, Antonio; Calverley, Peter M.A.
Journal:: Respiratory medicine
Issue:: Volume 143(2018)
Page Start:: 67
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗